Author:
Reck Martin,Dziadziuszko Rafal,Sugawara Shunichi,Kao Steven,Hochmair Maximilian,Huemer Florian,Castro Gilberto de,Havel Libor,Caro Reyes Bernabé,Losonczy György,Lee Jong-Seok,Kowalski Dariusz M.,Andric Zoran,Califano Raffaele,Veatch Andrea,Gerstner Gregory,Batus Marta,Morris Stefanie,Kaul Monika,Cuchelkar Vaikunth,Li Huafei,Danner Bradford J.,Nabet Barzin Y.,Liu Stephen V.
Reference10 articles.
1. Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives;Zhang;Front Oncol,2023
2. Prognostic value of clinical staging according to TNM in patients With SCLC: a real-world surveillance epidemiology and end-results database analysis;Arriola;JTO Clin Res Rep,2022
3. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients;Schabath;Lung Cancer,2014
4. L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, F. Huemer, G. Losonczy, M.L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D.S. Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S.V. Liu, I.M.S. Group, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, 379 (2018) 2220-2229.
5. Extensive-stage small-cell lung cancer: first-line and second-line treatment options;Zugazagoitia;J Clin Oncol,2022